Nuformix, a pharmaceutical development company, has signed an agreement with Quotient Clinical to conduct a pilot bioequivalence study for one of its lead programmes, NXP001, based on a currently marketed treatment in the field of oncology supportive care.
Quotient will use its Translational Pharmaceutics platform to evaluate bioequivalence for the NXP001 cocrystal product in healthy subjects.
Quotient's Translational Pharmaceutics platform integrates formulation development and real-time adaptive GMP manufacturing with clinical research. In comparison to traditional outsourcing approaches, Quotient's Translational Pharmaceutics platform dramatically accelerates drug product development timelines and significantly reduces development costs.
Nuformix hopes to realise these benefits in its NXP001 programme.
Dr Dan Gooding, CEO of Nuformix, said: "The appointment of Quotient was not a difficult decision as its Translational Pharmaceutics platform is perfectly suited to our needs in this final stage of our NXP001 programme - we were very impressed with Quotient's overall approach versus alternative options. Demonstrating NXP001's bioequivalence to the currently marketed product opens up immediate global out-licensing opportunities for Nuformix, so we're very excited to commence the study and also evaluate the platform's potential for future Nuformix clinical programmes."
At 9:53am: (LON:NFX) Nuformix Plc Ord 0.1p share price was -0.13p at 3.38p